• Privacy Policy
  • Terms and Conditions
  • Contact
Sunday, July 13, 2025
Pharma Info Nepal
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Updates

WHO Recommends Long Acting Cabotegravir for HIV Prevention

WHO Recommends Long Acting Cabotegravir for HIV Prevention

Pharma Info Nepal by Pharma Info Nepal
July 30, 2022
in Updates
0
WHO Recommends Long Acting Cabotegravir for HIV Prevention
248
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

WHO Recommends Long Acting Cabotegravir for HIV Prevention

New WHO guidelines advise countries to deliver long acting cabotegravir as part of comprehensive approach to HIV prevention

WHO released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe and highly effective prevention option for people at substantial risk of HIV infection.

The guidelines, released ahead of the 24th International AIDS Conference (AIDS 2022), will support countries as they plan for CAB-LA introduction as part of a comprehensive approach to HIV prevention and will facilitate urgently needed operational research.

The guidelines are launched at a critical moment, as HIV prevention efforts have stalled with 1.5 million new HIV infections in 2021 – the same as 2020. There were 4000 new infections every day in 2021, with key populations (sex workers, men who have sex with men, people who inject drugs, people in prisons and transgender people) and their sexual partners accounting for 70% of HIV infections globally.

“Long-acting cabotegravir is a safe and highly effective HIV prevention tool, but isn’t yet available outside study settings,” said Dr Meg Doherty, Director of WHO’s Global HIV, Hepatitis and Sexually Transmitted Infections Programmes. “We hope these new guidelines will help accelerate country efforts to start to plan and deliver CAB-LA alongside other HIV prevention options, including oral PrEP and the dapivirine vaginal ring.”

CAB-LA is an intramuscular injectable, long-acting form of PrEP, with the first 2 injections administered 4 weeks apart, followed thereafter by an injection every 8 weeks. CAB-LA was shown to be safe and highly effective among cisgender women, cisgender men who have sex with men, and transgender women who have sex with men in 2 randomized controlled trials, HPTN 083 and HPTN 084. Together, these landmark studies found that use of CAB-LA resulted in a 79% relative reduction in HIV risk compared with oral PrEP, where adherence to taking daily oral medication was often a challenge. Long-acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences.

Today’s press conference also marks the launch of a new coalition to accelerate global access to CAB-LA. Convened by WHO, Unitaid, UNAIDS and The Global Fund, the coalition will identify market interventions needed to advance near- and long-term access to CAB-LA, establish financing and procurement for the drug, provide implementation support to global HIV prevention programs and issue policy guidance, among other activities.

“To achieve UN prevention goals, we must push for rapid, equitable access to all effective prevention tools, including long-acting PrEP,” said Rachel Baggaley, Lead of the Testing, Prevention and Populations Team at Global HIV, Hepatitis and STI Programmes at WHO. “That means overcoming critical barriers in low- and middle-income countries, including implementation challenges and costs.”

WHO will continue to support evidence-based strategies to increase PrEP access and uptake, including through the adoption of CAB-LA. Key actions include:

WHO will support countries and partners to include CAB-LA safely and effectively in HIV prevention programmes.
WHO is working with Unitaid and other partners to develop implementation science projects to answer outstanding safety issues, implementation challenges, and understand people’s preferences for CAB-LA among other HIV prevention choices.
WHO is working with countries, communities and donors including The Global Fund, PEPFAR, and the Bill & Melinda Gates Foundation to support the inclusion of CAB-LA in their programmes and to catalyze implementation science and monitoring of programmes so that CAB-LA can be implemented, safely and effectively, for greatest impact.
The WHO Global PrEP Network will host webinars this year on CAB-LA to provide up-to-date information for countries, communities and implementers and increase awareness.
In April 2022, CAB-LA was added to WHO’s list of Expressions of Interest for evaluation for prequalification, and WHO is working with countries on regulatory approval.
Both oral PrEP and CAB-LA are highly effective. WHO will continue to support prevention choices. CAB-LA increases the options available and should always be offered alongside oral PrEP. Some people may continue to choose oral PrEP and CAB-LA will likely be preferred by people who find it difficult to take tablets or do not want to do so. WHO has also released new guidance on Differentiated and simplified PrEP at the AIDS 2022 conference to support easier access, including community delivery.

Consistent with previous WHO guidelines, the new CAB-LA guidelines are based on a public health approach that considers effectiveness, acceptability, feasibility and resource needs across a variety of settings. The guidelines are designed to facilitate CAB-LA delivery and the operational research which is urgently needed to address implementation and safety issues. These will inform decisions on how to successfully provide and scale up CAB-LA. The guidelines highlight critical research gaps, including issues relating to HIV drug resistance, HIV testing, service delivery models, resource requirements, safety in pregnancy and breastfeeding, and provision of CAB-LA in geographies and for populations not included in the trials.

The guidelines also note that young people and key populations often experience challenges in accessing current PrEP services. Communities must be involved in developing and delivering HIV prevention services that are effective, acceptable and support choice

Source: WHO



  • WHO Establishes the Global Centre for Traditional Medicine in India
  • Top 20 Drug and Medicine Name Origins
  • Why is a Separate Manufacturing Facility Required For Penicillin And Non Penicillin Products ?

 

Tags: Medicine InformationWHO
Previous Post

How to Use Mifepristone and Misoprostol

Next Post

Nepal Pharmacy Council License Exam Questions

Pharma Info Nepal

Pharma Info Nepal

Pharma Info Nepal is the leading platform for pharmacy professionals, students, and healthcare workers in Nepal. We provide verified job updates, exam preparation resources (NPC & Loksewa), scholarships, and professional guidelines. Trusted by thousands, we also share timely updates from DDA, NPC, and MoHP to keep the pharmacy community informed and empowered. Join us to grow, learn, and lead in Nepal’s pharmacy sector. Thanks for visiting us | Pharma Info Nepal: Nepal’s No.1 Pharmacy Blog

Related Posts

M. Pharmacy Colleges in Nepal
Colleges

M. Pharmacy Colleges in Nepal

July 8, 2025
List of CTEVT Constituent Colleges in Nepal
D Pharmacy

List of CTEVT Constituent Colleges in Nepal

June 29, 2025
Dapagliflozin Mechanism Uses Side Effects Contraindications and Dosage
Pharmacy Notes

Dapagliflozin: Mechanism, Uses, Side Effects, Contraindications, and Dosage

June 20, 2025
Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)
Updates

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)

June 15, 2025
Best NPC License Preparation Classes in Nepal for Pharmacy Students
License

Best NPC License Preparation Classes in Nepal for Pharmacy Students

May 22, 2025
WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook
Updates

WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook

May 21, 2025
Load More
Next Post
Nepal Pharmacy Council License Exam Questions

Nepal Pharmacy Council License Exam Questions

Discussion about this post

Recommended

Nepal Pharmacy Council License Exam Model Question Set - 1

Nepal Pharmacy Council License Exam Model Question Set – 1

July 10, 2025
PHARMA JOB VACANCIES NEPAL

Vacancy Announcement Pharmacist and Pharmacy Assistant Nepal Army

July 10, 2025
M. Pharmacy Colleges in Nepal

M. Pharmacy Colleges in Nepal

July 8, 2025
Pharmacist Job Vacancy Nepal

Vacancy Announcement Magnus Pharma Pvt. Ltd QA, QC, and Production

July 1, 2025
List of CTEVT Constituent Colleges in Nepal

List of CTEVT Constituent Colleges in Nepal

June 29, 2025
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

About Pharma Info Nepal

Pharma Info Nepal is a dedicated platform led by Nabin Bista, focused on empowering pharmacy students and professionals in Nepal. We provide high-quality educational resources, exam preparation materials, and professional guidance for pharmacy licensure exams and beyond. Our mission is to uplift the pharmacy profession in Nepal by fostering knowledge, skills, and excellence in pharmaceutical practice.

Explore our services, stay updated on pharmacy trends, and join a community striving for innovation and professionalism in healthcare.

Important Information

All content available on this website, including text, images, files, and other resources, is strictly protected under applicable copyright and intellectual property laws. Any reuse, reproduction, or redistribution of materials without prior written permission from Pharma Info Nepal is prohibited and may result in legal action.

Pharma Info Nepal operates as a registered company dedicated to maintaining the authenticity and integrity of its content and services.

Thank you for respecting our policies and supporting our mission to advance pharmacy education and practice.

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Pharmacy Notes
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
  • Pharmacy Notes

© 2025 Pharma Info Nepal | All Rights Reserved

error:
No Result
View All Result
  • Courses
  • Questions
  • Downloads
  • About Pharma Info Nepal 

© 2025 Pharma Info Nepal | All Rights Reserved